Celsion Corporation (CLSN) - NASDAQ
  • Mon, May 16, 8:36 AM
    • Celsion (CLSN) Q1 results: Revenues: $0.1M (unch); R&D Expense: $3.4M (-24.4%); SG&A: $1.9M (-5.0%); Operating Loss: ($5.2M) (+18.8%); Net Loss: ($5.7M) (+18.6%); Loss Per Share: ($0.24) (+31.4%); Quick Assets: $14.3M (+53.8%).
    • No guidance given.
    | Mon, May 16, 8:36 AM
  • Mon, May 16, 8:05 AM
    • Celsion (NASDAQ:CLSN): Q1 EPS of -$0.24 misses by $0.03.
    • Revenue of $0.13M (flat Y/Y) beats by $0.05M.
    • Press Release
    | Mon, May 16, 8:05 AM
  • Wed, Mar. 30, 9:22 AM
    • Celsion Corp. (CLSN) FY15 results: Revenues: $0.5M (unch); R&D Expense: $14.7M (-2.0%); SG&A: $6.7M (-24.7%); Operating Loss: ($20.8M) (+15.8%); Net Loss: ($22.5M) (+11.8%); Loss Per Share: ($1.03) (+25.4%); Quick Assets: $9.3M (-26.8%).
    • No guidance given.
    | Wed, Mar. 30, 9:22 AM
  • Wed, Mar. 30, 8:05 AM
    | Wed, Mar. 30, 8:05 AM
  • Nov. 5, 2015, 10:40 AM
    • Celsion Corp. (CLSN -1%) Q3 results: Revenues: $0.1M (unch); R&D Expense: $2.9M (-37.0%); SG&A: $1.5M (-25.0%); Operating Loss: ($4.2M) (+37.3%); Net Loss: ($4.3M) (+37.7%); Loss Per Share: ($0.19) (+52.5%); Quick Assets: $7.6M (-40.2%).
    • No guidance given.
    | Nov. 5, 2015, 10:40 AM
  • Nov. 5, 2015, 8:06 AM
    • Celsion (NASDAQ:CLSN): Q3 EPS of -$0.19 may not be comparable to consensus of -$0.26.
    • Revenue of $0.13M (flat Y/Y) beats by $0.02M.
    | Nov. 5, 2015, 8:06 AM
  • Aug. 10, 2015, 9:36 AM
    • Celsion Corp. (CLSN) Q2 results: Revenues: $0.1M (unch); R&D Expense: $3.6M (+12.5%); SG&A: $1.8M (-21.7%); Operating Loss: ($5.2M) (+18.8%); Net Loss: ($5.7M) (+14.9%); Loss Per Share: ($0.27) (+28.9%); Quick Assets: $12M (-5.5%).
    • No guidance given.
    | Aug. 10, 2015, 9:36 AM
  • Aug. 10, 2015, 8:02 AM
    • Celsion (NASDAQ:CLSN): Q2 EPS of -$0.27 beats by $0.04.
    • Revenue of $0.13M (flat Y/Y) beats by $0.02M.
    | Aug. 10, 2015, 8:02 AM | 1 Comment
  • May 12, 2015, 8:47 AM
    • Celsion Corp. (CLSN +2%) Q1 results: Revenues: $0.1M (unch); R&D Expense: $4.5M (+55.2%); SG&A: $2M (-16.7%); Operating Loss: ($6.4M) (-23.1%); Net Loss: ($7M) (-29.6%); Loss Per Share: ($0.35) (-6.1%); Quick Assets: $7.6M (-40.2%).
    • No guidance given.
    | May 12, 2015, 8:47 AM
  • May 12, 2015, 8:03 AM
    • Celsion (NASDAQ:CLSN): Q1 EPS of -$0.35 misses by $0.02.
    • Revenue of $0.13M in-line (flat Y/Y).
    | May 12, 2015, 8:03 AM
  • Mar. 12, 2015, 9:46 AM
    • Celsion Corp. (CLSN -1.4%) FY14 results: Revenues: $0.5M (unch); R&D Expense: $15M (+59.6%); SG&A: $8.9M (+36.9%); Operating Loss: ($24.7M) (-60.4%); Net Loss: ($25.5M) (-102.4%); Loss Per Share: ($1.38) (-45.3%); Quick Assets: $12.7M (+122.8%).
    • No guidance given.
    | Mar. 12, 2015, 9:46 AM
  • Mar. 12, 2015, 8:04 AM
    • Celsion (NASDAQ:CLSN): FY14 EPS of -$1.38
    • Revenue of $0.5M
    | Mar. 12, 2015, 8:04 AM
  • Nov. 12, 2014, 12:18 PM
    • Celsion Corp. (CLSN +2%) Q3 results: Revenues: $0.13M (unch); R&D Expense: $4.6M (+100.0%); G&A: $2M (+42.9%); Operating Loss: ($6.7M) (-91.4%); Net Loss: ($6.9M) (-68.3%); Loss Per Share: ($0.35) (-16.7%); Quick Assets: $43.8M (+1.6%).
    • No guidance given.
    | Nov. 12, 2014, 12:18 PM
  • Nov. 11, 2014, 12:58 PM
    • Celsion (NASDAQ:CLSN): Q3 EPS of -$0.35 misses by $0.03.
    • Revenue of $0.13M in-line (flat Y/Y).
    | Nov. 11, 2014, 12:58 PM
  • Nov. 4, 2014, 11:50 AM
    • Celsion (CLSN -3%) will report Q3 results on November 11 after the close. The conference call will begin at 4:30 pm ET.
    • Consensus view is a loss of ($0.32) per share on revenues of $150K.
    | Nov. 4, 2014, 11:50 AM
Company Description
Celsion Corp. engages in the provision of oncology drug development services. It operates through developing and commercializing chemotherapeutic oncology drugs based on proprietary heat-activated liposomal technology. Its products include ThermoDox, TheraPlas, and TheraSilence. The company was... More
Sector: Healthcare
Industry: Biotechnology
Country: United States